Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 10, showing 5 Applications out of 50 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s)

1.

ECCT/24/02/04   IGHID 12333
    IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya.IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya.   
Principal Investigator(s)
1. Chemtai Mungo
Site(s) in Kenya
Lumumba subcounty Hospital Kisumu
 
View

2.

ECCT/24/01/01   SAVIS
    A Phase 1 Clinical Study to Evaluate the Safety and Immunogenicity of a Novel GMMA Vaccine Against Invasive Non-Typhoidal Salmonella in healthy Kenyan adults.      
Principal Investigator(s)
1. ANTHONY SCOTT
Site(s) in Kenya
KEMRI Centre for Geographical Medicine Research Coast
 
View

3.

ECCT/23/11/04   AUB Study
    A phase 1, single-center, double-blind, randomized, placebo-controlled trial to assess the safety, tolerability and initial efficacy of AHC01 delivered via transcervical catheter in adult females (25-55 years), experiencing abnormal uterine bleeding and scheduled for a hysterectomy.   
Principal Investigator(s)
1. Dr Alice Kaaria
Site(s) in Kenya
Kenyatta National Hospital (KNH)
 
View

4.

ECCT/23/11/02   CROSSWALK Acute (A)
    A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD)   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. In this submission: International Cancer Institute (Uasin Gishu county)
 
View

5.

ECCT/23/10/02   MATRIX-001 protocol
    A Phase I Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Pharmacokinetics, and Modeled Pharmacodynamics of a Vaginal Insert Containing Tenofovir Alafenamide and Elvitegravir       
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD Thika
 
View